Key Takeaways
- Semaglutide and tirzepatide are the only weight-loss peptides with large human RCT evidence; tirzepatide (15 mg) produced mean weight reduction of approximately 21% in the SURMOUNT-1 trial (n=2,539) at 72 weeks.
- AOD-9604, despite widespread marketing claims, failed its only Phase 2 RCT for weight loss; development was abandoned by Metabolic Pharmaceuticals.
- CJC-1295 and ipamorelin raise GH and IGF-1 measurably in small human studies, but no RCT has demonstrated them as primary weight-loss agents in overweight populations.
- Research-grade peptide vials are not GMP-certified; published analyses of commercial research peptides have found significant purity variation and, in some cases, wrong compounds entirely.
- The FDA has issued multiple warnings about counterfeit semaglutide from compounding pharmacies and online suppliers; at least one serious adverse event cluster has been linked to contaminated product.
What Are the Best Weight Loss Peptides?
The best weight loss peptides are semaglutide and tirzepatide, both FDA-approved, both with multiple phase 3 RCTs showing 15-21% body weight reduction. Every other peptide discussed in this space (CJC-1295, ipamorelin, AOD-9604, BPC-157) has either failed human trials or never been tested in one at adequate power. That hierarchy matters before you read anything else on this page.
Table of Contents
- Evidence Ledger: Every Major Claim Graded
- Tier 1: FDA-Approved GLP-1/GIP Peptides
- Tier 2: GH Secretagogues (CJC-1295, Ipamorelin)
- Tier 3: Failed and Fringe Peptides (AOD-9604, BPC-157)
- Mechanism With Numbers: How GLP-1 Agonists Work
- What Most Pages Get Wrong About Weight Loss Peptides
- Honest Head-to-Head Comparison Table
- Chemistry Behind the Storage and Stability Rules
- Operational Guide: COA Reading, Reconstitution Math, Dosing
- FAQ
- Sources
What Does the Evidence Actually Show for Each Peptide?
The table below grades every major efficacy claim. Evidence type is the highest-quality evidence available; effect direction is the best-supported direction from that evidence tier.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Peptide | Best Evidence Type | Effect Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| Semaglutide (2.4 mg SC weekly) | Multiple Phase 3 RCTs (STEP 1-4, SELECT; thousands of participants) | Significant weight reduction (~15% mean, STEP 1) | High | Weight regain on discontinuation; GI side effects in majority |
| Tirzepatide (up to 15 mg SC weekly) | Phase 3 RCTs (SURMOUNT-1, SURMOUNT-5) | Significant weight reduction (~21% mean, SURMOUNT-1) | High | Higher cost; no long-term cardiovascular outcomes trial completed yet for obesity indication |
| CJC-1295 + Ipamorelin | Small human pharmacokinetic studies; animal body composition data | Raises GH/IGF-1; may shift body composition | Low | No RCT with weight loss as primary endpoint in overweight adults |
| AOD-9604 | Phase 2 RCT (Metabolic Pharmaceuticals, ~300 participants) | No significant weight loss vs. placebo | Moderate (for null result) | Rodent lipolysis data do not translate; program discontinued |
| BPC-157 | Rodent studies only | No evidence for fat loss | Very Low | Mechanism is tissue repair, not lipolysis; no human trial data |
| Hexarelin | Small human studies (GH release); animal fat-pad data | GH increase; no meaningful weight loss signal in humans | Very Low | Rapid desensitization limits sustained effect |
Tier 1: What Do the FDA-Approved Weight Loss Peptides Actually Do?
Semaglutide (Wegovy / Ozempic)
Semaglutide is a 31-amino-acid GLP-1 receptor agonist with approximately 94% homology to native human GLP-1. The critical structural difference is a C-18 fatty diacid side chain attached at position 26 (lysine), which binds albumin reversibly and extends plasma half-life to roughly 7 days, enabling once-weekly dosing. The STEP 1 trial (n=1,961) showed a mean 14.9% weight reduction at 68 weeks versus 2.4% for placebo. The SELECT trial (n=17,604, people with cardiovascular disease but without diabetes) demonstrated a 20% reduction in major adverse cardiovascular events -- the only weight-loss peptide with this outcome data.
What this does NOT prove: that the weight loss is permanent. The STEP 4 withdrawal extension showed rapid weight regain (roughly two-thirds of lost weight returned within a year of stopping).
Tirzepatide (Zepbound / Mounjaro)
Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. It is a 39-amino-acid synthetic peptide not derived from either native hormone. SURMOUNT-1 (n=2,539) demonstrated a mean 20.9% weight reduction at 15 mg over 72 weeks. SURMOUNT-5, the first direct head-to-head RCT against semaglutide 2.4 mg, showed tirzepatide produced approximately 47% greater relative weight loss (reported 2024). The mechanism behind the additive GIP effect is still under active investigation; GIP receptors in adipose tissue and the CNS are both implicated.
Tier 2: Do GH Secretagogues Like CJC-1295 and Ipamorelin Help With Fat Loss?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that, in its DAC (Drug Affinity Complex) form, binds albumin and extends its half-life from minutes to several days. Ipamorelin is a pentapeptide ghrelin mimetic that selectively stimulates GH release with minimal effect on cortisol or prolactin -- a selectivity advantage over older secretagogues like GHRP-2.
A published pharmacokinetic study in healthy adults (Ionescu and Frohman, Journal of Clinical Endocrinology and Metabolism, 2006, n=21) confirmed CJC-1295 (with DAC) increased mean GH levels 2-10 fold and IGF-1 by roughly 20-30% over baseline at doses of 30-60 mcg/kg. These are real hormonal changes. However, elevated GH and IGF-1 shifting body composition and causing clinically meaningful weight loss in already-overweight adults is a separate, unproven step. The evidence that GH therapy in GH-sufficient overweight people produces durable fat loss is weak. Using secretagogues as a proxy for GH therapy adds another layer of uncertainty.
Legitimate use case: Body composition in GH-deficient or older adults, where there is more mechanistic rationale. Not weight loss as a standalone intervention in healthy overweight individuals.
Tier 3: Why Did AOD-9604 Fail, and What About BPC-157?
AOD-9604 (amino acids 176-191 of human growth hormone) was rationally designed to isolate GH's lipolytic activity from its growth-promoting activity. It showed compelling rodent data. Metabolic Pharmaceuticals ran a Phase 2 trial in overweight adults and found no statistically significant weight loss versus placebo. The compound did receive a US GRAS (Generally Recognized as Safe) designation for use as a food ingredient, which some marketers misrepresent as evidence of efficacy. It is not.
BPC-157 is a 15-amino-acid peptide derived from a gastric protein. Its published research is almost entirely in rodent models and focuses on wound healing, tendon repair, and gut mucosal protection. There is no plausible or demonstrated lipolytic mechanism. Its repeated appearance on "best weight loss peptide" lists reflects marketing, not evidence.
How Do GLP-1 Agonist Peptides Cause Weight Loss at the Molecular Level?
GLP-1 (glucagon-like peptide-1) is an incretin secreted by L-cells in the distal gut in response to nutrient ingestion. Native GLP-1 has a plasma half-life of approximately 1-2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide resists DPP-4 cleavage via two structural modifications: an aminoisobutyric acid substitution at position 8 (replacing alanine) and the C-18 fatty acid chain enabling albumin binding, extending half-life to approximately 7 days.
The GLP-1 receptor is expressed in the pancreas (beta cells, where it stimulates glucose-dependent insulin secretion), in the vagus nerve and brainstem nucleus tractus solitarius, and in hypothalamic appetite centers including the arcuate nucleus. Appetite suppression -- not just delayed gastric emptying -- is now understood to be the primary driver of weight loss based on CNS receptor distribution studies and the observation that nausea (a GI effect) does not correlate well with weight-loss magnitude across patients.
What this mechanism does NOT prove: that the weight loss is metabolically unique. A 2023 analysis suggested a significant portion of weight lost on GLP-1 agonists is lean mass, not purely fat -- a concern for long-term metabolic health that is under active investigation.
What Most Pages Get Wrong About Weight Loss Peptides
This is the section commodity pages skip.
- Oral bioavailability is near zero for most peptides. Peptides above about 500 daltons are cleaved by GI proteases before systemic absorption. Oral "peptide supplements" containing these compounds are consuming degraded amino acids, not intact peptides. The exception is semaglutide oral (Rybelsus), which uses an absorption enhancer (SNAC) and achieves roughly 1% oral bioavailability -- enough to work but requiring specific fasting conditions to reach even that level.
- Purity claims from research suppliers are frequently unverified. A 2018 analysis published in Pharmacological Research examining research-grade peptide vials from online suppliers found significant variability in actual peptide content compared to labeled claims, and at least some samples contained incorrect or additional compounds. A COA from the same supplier manufacturing the product is not independent verification.
- The GH secretagogue + fat loss claim depends on a healthy GH axis. Ipamorelin and CJC-1295 work by amplifying existing GH pulsatility. In people with suppressed GH (obesity itself suppresses GH secretion), the response may be blunted, which is exactly the population most interested in fat loss.
- Compounded semaglutide availability is legally conditional. FDA permitted 503A/503B compounding of semaglutide only during the documented shortage period. As of early 2025, the FDA declared the shortage resolved and began enforcement action against compounders. The legal status of compounded semaglutide is not stable and varies by jurisdiction and timing.
Honest Head-to-Head: Best Weight Loss Peptides vs. Each Other and vs. Non-Peptide Alternatives
| Agent | Avg. Weight Loss (Human RCT) | Evidence Level | Route | Regulatory Status | Where It Loses |
|---|---|---|---|---|---|
| Tirzepatide 15 mg | ~21% (SURMOUNT-1) | High | SC weekly injection | FDA-approved (Zepbound) | Cost (~$1,000+/month without insurance); GI side effects; no long-term CV outcome data for obesity yet |
| Semaglutide 2.4 mg | ~15% (STEP 1) | High | SC weekly injection | FDA-approved (Wegovy) | Less weight loss than tirzepatide; weight regain on stopping |
| CJC-1295 + Ipamorelin | No RCT data for weight as endpoint | Low | SC daily injection | Not approved; research compound | No proof of weight loss; IGF-1 elevation; unregulated supply |
| AOD-9604 | No significant effect (Phase 2 failed) | Moderate (null) | SC injection | Not approved | Does not work in humans at tested doses |
| Orlistat (non-peptide) | ~3-4% vs. placebo (multiple RCTs) | High | Oral TID | FDA-approved (OTC and Rx) | Modest effect size; GI side effects (steatorrhea) |
| Phentermine/topiramate ER (non-peptide) | ~9-10% (CONQUER trial) | High | Oral daily | FDA-approved (Qsymia) | CNS side effects; teratogenicity risk; controlled substance |
Why Do Storage and Stability Rules Exist? The Chemistry Explained
Lyophilized (freeze-dried) peptides are stable because removing water halts the two primary degradation pathways: hydrolysis (water attacking amide bonds in the peptide backbone) and oxidation (reactive oxygen species attacking methionine, cysteine, or tryptophan residues). At -20°C in lyophilized form, both pathways slow to negligible rates.
Once you add bacteriostatic water to reconstitute, you reintroduce water and start the hydrolysis clock. Refrigeration at 2-8°C slows but does not stop degradation. The 28-day rule for reconstituted peptides is a practical estimate, not a precise kinetic endpoint -- some peptides degrade faster (those with more susceptible residues like Met or Trp), some slower.
Why you should not use saline for reconstitution if you plan to store: Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends usability. Sterile water for injection (SWFI) has no preservative and should be used immediately. This is not a marketing preference -- it is microbial contamination chemistry.
Why freeze-thaw cycles degrade peptides: Ice crystal formation mechanically disrupts protein/peptide structure and concentrates solutes locally, accelerating chemical degradation. Each freeze-thaw cycle causes incremental, cumulative loss. Aliquot before freezing if you intend to use across multiple doses.
Why vitamin C (ascorbic acid) is incompatible in the same solution as many peptides: Ascorbic acid is a reducing agent. In the presence of dissolved oxygen, it can reduce and then re-oxidize, generating hydrogen peroxide and free radicals that attack susceptible amino acid residues. Formulations that combine peptides with vitamin C in a single product are chemically unstable over time, regardless of what the label claims.
How Do You Actually Evaluate a Weight Loss Peptide Product? COA Reading and Reconstitution Math
Reading a COA: Minimum Requirements
| Parameter | Minimum Standard | Red Flag |
|---|---|---|
| HPLC Purity | Greater than or equal to 98% | Less than 95%, or no method stated |
| Mass Spectrometry | Molecular weight matches theoretical within 1 Da | No MS confirmation; "purity by HPLC only" |
| Testing Laboratory | Named, third-party, accredited (ISO 17025 preferred) | In-house lab; no lab name; no accreditation |
| Endotoxin (LAL test) | Less than 1 EU/mg for injectable peptides | Not tested; result not provided |
| Lot Number | Must match vial label | Generic or missing lot number |
Reconstitution Math (Example)
Vial contents: 5 mg peptide. Bacteriostatic water added: 2 mL. Resulting concentration: 5 mg / 2 mL = 2.5 mg/mL.
To draw 0.25 mg: 0.25 / 2.5 = 0.10 mL = 10 units on a U100 (100 units/mL) insulin syringe.
To draw 0.5 mg: 0.5 / 2.5 = 0.20 mL = 20 units on a U100 syringe.
Labeling error and measurement error at small volumes are clinically significant. A 0.01 mL error on a 0.1 mL draw is a 10% dose error.
What Degraded Peptide Looks Like
- Cloudiness or particulate matter in a solution that was previously clear
- Yellow or brown discoloration (oxidation of aromatic residues)
- Loss of expected physiological effect at a previously effective dose (harder to assess without bloodwork)
- Unusual odor on reconstitution (rare but possible with severe degradation)
FAQ
What are the best weight loss peptides backed by human clinical data?
Semaglutide and tirzepatide have the strongest human RCT evidence, with average body weight reductions of roughly 15% and 21% respectively in 68-72 week trials. All other weight-loss peptides (CJC-1295, ipamorelin, BPC-157, AOD-9604) have only animal or very small human data.
How do GLP-1 receptor agonist peptides cause weight loss?
GLP-1 receptor agonists slow gastric emptying, suppress glucagon, and act on hypothalamic and brainstem appetite centers to reduce caloric intake. Semaglutide binds the GLP-1 receptor with roughly 94% amino-acid homology to native GLP-1 but has a fatty-acid side chain that extends its half-life to approximately 7 days.
Is tirzepatide better than semaglutide for weight loss?
Head-to-head data from the SURMOUNT-5 trial showed tirzepatide (10-15 mg) produced roughly 47% greater relative weight loss than semaglutide 2.4 mg over 72 weeks. Tirzepatide's dual GLP-1/GIP agonism appears to confer additive benefit, but it also carries a higher list price and similar GI side-effect profile.
What is AOD-9604 and does it actually burn fat?
AOD-9604 is a 16-amino-acid fragment (176-191) of human growth hormone that showed lipolytic activity in rodent studies without causing IGF-1 elevation. Its single Phase 2 human trial in obese adults did not demonstrate statistically significant weight loss beyond placebo. Development was discontinued.
Can CJC-1295 and ipamorelin help with fat loss?
CJC-1295 (with DAC) extends GHRH signaling to produce sustained GH pulses; ipamorelin is a selective ghrelin mimetic. Together they raise GH and IGF-1, which can shift body composition toward less fat and more lean mass. However, no large RCT has shown meaningful weight reduction as a primary endpoint in overweight humans.
Are research peptides like BPC-157 and TB-500 useful for weight loss?
No. BPC-157 and TB-500 (thymosin beta-4 fragment) act primarily on tissue repair and angiogenesis. Neither has any credible mechanism or evidence for meaningful fat loss in humans. Their use for weight loss is unsupported by the literature.
What are the real risks of using compounded or research peptides for weight loss?
Risks include unknown purity (research-grade suppliers are not GMP-certified), incorrect dosing from imprecise reconstitution, injection-site reactions, and, for GH secretagogues, potential IGF-1 elevation that carries theoretical long-term oncologic risk. Counterfeit semaglutide from unregulated sources has caused serious adverse events.
How do I reconstitute and dose a peptide like semaglutide or CJC-1295?
Divide the vial's total peptide content (in mg) by the bacteriostatic water volume added (in mL) to get mg/mL concentration, then calculate your draw volume. For example, 5 mg semaglutide in 2 mL water = 2.5 mg/mL; a 0.25 mg dose requires 0.1 mL (10 units on a U100 insulin syringe).
How should weight loss peptides be stored and what does degradation look like?
Lyophilized peptides are stable at 2-8 degrees C for months and at -20 degrees C for longer. Once reconstituted, most peptides should be used within 28-30 days refrigerated. Degraded solution may appear cloudy, particulate, or discolored. Repeated freeze-thaw cycles break peptide bonds and reduce potency.
Does the FDA regulate weight loss peptides?
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved drugs. Most other peptides discussed for weight loss (CJC-1295, ipamorelin, AOD-9604, BPC-157) are not FDA-approved for any indication and are sold legally only as research chemicals not intended for human use, or as compounded preparations by 503A/503B pharmacies under specific conditions.
What should I look for on a certificate of analysis (COA) for a peptide?
A credible COA should show HPLC purity of at least 98%, mass spectrometry confirmation of the correct molecular weight, the testing lab's name and accreditation, the lot number, and residual solvent and endotoxin levels. A COA that lists only purity by HPLC without MS confirmation is insufficient.
Which weight loss peptide has the best safety profile for long-term use?
Among approved agents, semaglutide has the longest post-market safety record for weight management (approved 2021 for obesity). The SELECT cardiovascular outcomes trial (17,604 participants) showed a significant reduction in MACE events, adding a safety-plus signal. GI side effects remain the primary tolerability limit.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232.
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28(10):2083-2091.
- Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797.
- Heffernan M, et al. The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5051-5057.
- Metabolic Pharmaceuticals. AOD9604 Phase 2 clinical trial results. Disclosed in company communications and regulatory filings, referenced in: Dehkhoda F, et al. Frontiers in Endocrinology. 2018;9:44.
- FDA. Wegovy (semaglutide) prescribing information. NDA 215256. Approved June 2021.
- FDA. Zepbound (tirzepatide) prescribing information. NDA 217806. Approved November 2023.
- FDA. Counterfeit semaglutide products -- safety communication. 2024. Available at: fda.gov.
- Heymsfield SB, et al. Mechanisms, Pathophysiology, and Management of Obesity. New England Journal of Medicine. 2017;376(3):254-266.
- Erdmann J, et al. Role of GIP in the regulation of body weight. Peptides. 2022;154:170817. (Background on dual GIP/GLP-1 mechanism of tirzepatide.)